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Abstract
Hypertriglyceridemia (triglycerides > 150 mg/dL) affects ~25 % of the United States (US) population and is associated
with increased cardiovascular risk. Severe hypertriglyceridemia (≥ 500 mg/dL) is also a risk factor for pancreatitis. Three
omega-3 fatty acid (OM3FA) prescription formulations are approved in the US for the treatment of adults with severe
hypertriglyceridemia: (1) OM3FA ethyl esters (OM3EE), a mixture of OM3FA ethyl esters, primarily eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) (Lovaza®, Omtryg™, and generics); (2) icosapent ethyl (IPE), EPA ethyl esters
(Vascepa®); and (3) omega-3 carboxylic acids (OM3CA), a mixture of OM3FAs in free fatty acid form, primarily EPA,
DHA, and docosapentaenoic acid (Epanova®). At approved doses, all formulations substantially reduce triglyceride and
very-low-density lipoprotein levels. DHA-containing formulations may also increase low-density lipoprotein cholesterol.
However, this is not accompanied by increased non-high-density lipoprotein cholesterol, which is thought to provide
a better indication of cardiovascular risk in this patient population. Proposed mechanisms of action of OM3FAs include
inhibition of diacylglycerol acyltransferase, increased plasma lipoprotein lipase activity, decreased hepatic lipogenesis,
and increased hepatic β-oxidation. OM3CA bioavailability (area under the plasma concentration-time curve from zero
to the last measurable concentration) is up to 4-fold greater than that of OM3FA ethyl esters, and unlike ethyl esters,
the absorption of OM3CA is not dependent on pancreatic lipase hydrolysis. All three formulations are well tolerated
(the most common adverse events are gastrointestinal) and demonstrate a lack of drug-drug interactions with other
lipid-lowering drugs, such as statins and fibrates. OM3FAs appear to be an effective treatment option for patients with
severe hypertriglyceridemia.
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Background
Hypertriglyceridemia, defined as a triglyceride (TG) level
of > 150 mg/dL, affects approximately 25 % of the
United States (US) population [1]. High levels of TG
(≥ 200 mg/dL) have been shown to be independently asso-
ciated with an increased risk of cardiovascular disease
(CVD), even in patients treated effectively with statins to
reduce low-density lipoprotein cholesterol (LDL-C) [2, 3].
With increased TG, there are elevations of TG-rich lipo-
proteins (TRL) (very-low-density lipoproteins [VLDL] plus
chylomicrons) and their remnants which have been shown
to contribute to the progression of atherosclerosis and
CVD via a number of direct and indirect mechanisms.
These mechanisms include the direct contribution to
intimal cholesterol deposition, and the activation and
enhancement of pro-inflammatory, pro-apoptotic, and
pro-coagulant pathways [4].
Severe hypertriglyceridemia, defined by the 2014
National Lipid Association (NLA) guidelines as a TG
level of ≥ 500 mg/dL [5], is also a well-known risk factor
for pancreatitis, reportedly causing up to 7 % of cases
[6]. Severe hypertriglyceridemia usually occurs as a
result of one or more genetic disorders, such as
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hyperlipoproteinemia or lipoprotein lipase (LPL) defi-
ciency [7]. In this instance, elevated levels of chylomi-
crons are thought to obstruct capillaries in the pancreas,
leading to local ischemia, edema, and inflammation [6].
Consequently, it is important that patients with hypertri-
glyceridemia receive safe and effective treatment to reduce
the risk of pancreatitis and CVD. In severe hypertrigly-
ceridemia, guidelines advocate the immediate use of TG-
lowering drugs [5, 8], which include fibrates, niacin, and
omega-3 fatty acids (OM3FAs). However, in patients with
moderately elevated TG, statins are often recommended as
first-line therapy. Although statins primarily target elevated
LDL-C, in patients with high baseline TG levels (≥ 273 mg/
dL), some high-intensity statins have been shown to reduce
TG by up to 43 % [9]. That said, if elevated TG or non-
high-density lipoprotein cholesterol (non-HDL-C) levels
persist following lifestyle intervention and statin therapy, a
number of guidelines recommend the addition of a TG-
lowering drug [5]. Although all of these drugs successfully
lower TG levels, the high incidence of adverse events asso-
ciated with niacin therapy and the increased incidence of
myopathy and rhabdomyolysis observed with some fibrate-
statin combinations have raised concerns [10, 11]. In April
2016, the Food and Drug Administration (FDA) concluded
that the benefits of the concomitant use of statins plus
extended release niacin or some fibrates do not outweigh
the risks, and have, therefore, withdrawn the approvals for
this indication [12]. However, the indications for the treat-
ment of severe hypertriglyceridemia remain intact. It has
been suggested that OM3FAs may be a well-tolerated and
effective alternative to fibrates and niacin in the treatment
and management of hypertriglyceridemia [13].
Prescription formulations of OM3FAs are indicated in
the US as an adjunct to diet to reduce TG levels in adults
with severe hypertriglyceridemia. There are three prescrip-
tion OM3FA formulations approved in the US: (1) omega-
3 fatty acid ethyl esters (OM3EE), a mixture of long-chain
omega-3 fatty acid ethyl esters, primarily eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA) (Lovaza®,
Omtryg™, and some generics) [14, 15]; (2) icosapent ethyl
(IPE), EPA ethyl esters (Vascepa®) [16]; (3) and omega-3
carboxylic acids (OM3CA), a mixture of long-chain
OM3FAs in free fatty acid form, primarily EPA, DHA, and
docosapentaenoic acid (DPA) (Epanova®) [17]. Of note,
although Epanova and Omtryg have been approved in the
US by the FDA, and Epanova is currently being studied in
the prevention of adverse cardiovascular outcomes, they
are not yet commercially available. Although these pre-
scription formulations have all been shown to significantly
reduce TG levels in patients with high or very high TG
levels, and they appear to be generally well tolerated in
these patient populations, they differ in their effects on
individual lipid parameters and bioavailability [18–24].
OM3FA dietary supplements are also available, but as
these products do not need to comply with the rigorous
regulations required for prescription formulations, and do
not require approval from the FDA, their OM3FA content
is often inconsistent and may be inadequate to effectively
treat hypertriglyceridemia [25–27].
This review aims to evaluate the clinical relevance of
OM3FAs in the management of hypertriglyceridemia and
to explore the pharmacological and mechanistic proper-
ties, as well as the efficacy and safety, of three prescription
OM3FA formulations.
Search strategy
A search of PubMed was performed using the following
search strategy: (“Hypertriglyceridemia”[MeSH]) AND
“Fatty Acids, Omega-3”[MeSH]).
The search was limited to English-language, human-
only studies published from August 17, 2005, to August
17, 2015. The literature search yielded a total of 166 pub-
lications. The reference lists of articles identified using this
search strategy were also searched, meaning that widely
referenced, older publications were also screened. Articles
were deemed eligible for inclusion if they provided useful
and clinically relevant information pertaining to prescrip-
tion formulations of OM3FAs, or the treatment and
management of hypertriglyceridemia. In addition, the US
prescribing information for prescription OM3FAs and
current guidelines on the treatment and management of
dyslipidemia were reviewed.
Management of hypertriglyceridemia
The clinical definitions of hypertriglyceridemia, as out-
lined in the 2014 NLA guideline on the management of
dyslipidemia, are shown in Table 1. However, it is impor-
tant to note that the precise clinical definitions of the
severity of hypertriglyceridemia differ among guidelines.
For example, although severe hypertriglyceridemia is typ-
ically classified as a TG level ≥ 500 mg/dL [5, 28–30], the
2012 Endocrine Society guideline and the 2014 American
Diabetes Association guideline classify severe hypertrigly-
ceridemia as a TG level ≥ 1000 mg/dL [31, 32]. The majo-
rity of guidelines agree that a TG level of < 150 mg/dL is
desirable [5, 28–31, 33, 34].
Although current guidelines advocate the immediate use
of a TG-lowering drug in patients with very high TG levels
(≥ 500 mg/dL) and recommend that lifestyle intervention
Table 1 Clinical definition of hypertriglyceridemia [5]
Category TG, mg/dL (mmol/L)
Normal < 150 (< 1.7)
Borderline-high 150–199 (1.7–2.2)
High 200–499 (2.2–5.6)
Very high (severe HTG) ≥ 500 (≥ 5.6)
HTG hypertriglyceridemia, TG triglyceride
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and statin treatment should be considered as first-line
therapy in patients with moderately elevated TG, they can
vary in some aspects of their treatment and management
recommendations [5, 28–31, 33, 34]. The 2014 NLA
guideline recommends using LDL-C or non-HDL-C as
the primary treatment target in patients with dyslipidemia.
They also emphasize that as non-HDL-C comprises all
the cholesterol carried by potentially atherogenic lipopro-
tein particles, it is a stronger predictor of CVD than LDL-
C. In addition, they consider apolipoprotein B (ApoB) as
an optional secondary treatment target [5]. This guidance
is in contrast to the 2013 American College of Cardiology
(ACC)/American Heart Association (AHA) guideline,
which focuses on the use of fixed-dose, moderate- to
high-intensity statin therapy to reduce LDL-C levels in
patients at high CVD risk [8].
Like most guidelines, neither the NLA nor ACC/AHA
guideline considers elevated TG to be a treatment target
unless levels are very high (≥ 500 mg/dL). The NLA guide-
line highlights that in this case, TG lowering becomes the
primary management goal, and the immediate use of a
TG-lowering drug, including high-dose OM3FAs, is war-
ranted [5]. Although the ACC/AHA guideline does not
make any specific recommendations for the treatment of
patients with very high TG levels, it does direct the reader
to the 2011 AHA scientific statement on TG and CVD,
which recommends the use of pharmacological therapy
with a TG-lowering drug, including fibrates, niacin, or
OM3FAs [28].
In the management of elevated TG levels, both the 2014
NLA guideline and the 2011 AHA scientific statement
focus on intensive therapeutic lifestyle intervention,
including a 5–10 % reduction in body weight, restriction
of alcohol and sugar intake, and increased physical activity
[5, 28]. The NLA guideline also states that when TG levels
are high (200–499 mg/dL), non-HDL-C remains the
primary treatment target, and statins the first-line therapy
choice. However, if non-HDL-C treatment goals (< 130 mg/
dL for low- to high-risk patients or < 100 mg/dL for very-
high-risk patients) are not achieved with the maximum
tolerated statin therapy, the guideline advocates the
addition of a TG-lowering drug, such as OM3FAs, fibrates,
or niacin, to statin therapy in patients with hypertrigly-
ceridemia [5].
Like the 2014 NLA guideline, a number of other
guidelines pertaining to the treatment and management
of hypertriglyceridemia also recommend the use of TG-
lowering drugs (including high-dose OM3FAs), alone or
in combination with statin therapy, in patients who
continue to have elevated TG or non-HDL-C levels des-
pite being at LDL-C treatment goal [31, 33, 34]. That
being said, as mentioned previously, in 2016 the FDA
withdrew the approval for extended release niacin and
some fibrates when coadministered with statins [12].
Mechanism of action of omega-3 fatty acids
Although the TG-lowering ability of prescription OM3FAs
is well established, the exact TG-lowering mechanisms of
action are not completely understood. Results from pre-
clinical and clinical studies suggest that OM3FAs decrease
serum TG concentrations by reducing TG synthesis,
reducing the incorporation of TG into VLDL, reducing
TG secretion, and enhancing TG clearance from VLDL
particles [35] (Fig. 1). It has been proposed that OM3FAs
exert these TG-lowering effects via a number of mecha-
nisms: (1) OM3FAs are thought to decrease hepatic
Fig. 1 Proposed mechanisms of action of prescription formulations of long-chain omega-3 fatty acids. ApoCIII apolipoprotein CIII, Acetyl Co-A
acetyl coenzyme A, DGAT diglyceride acyltransferase; FA fatty acid, LPL lipoprotein lipase, TG triglyceride, VLDL very-low-density lipoprotein
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lipogenesis by suppressing the expression of sterol regula-
tory element-binding protein-1c. This, in turn, leads to
decreased expression of cholesterol-, fatty acid-, and TG-
synthesizing enzymes [36, 37]. (2) They are thought to
increase the β-oxidation of fatty acids, resulting in a
reduction in available substrate required for TG and
VLDL synthesis [35]. (3) They are thought to inhibit key
enzymes involved in hepatic TG synthesis, such as phos-
phatidic acid phosphatase and diacylglycerol acyltrans-
ferase [38]. (4) Finally, they have been shown to increase
the expression of LPL, a key component of the TRL
biosynthetic pathways, leading to increased TG removal
from circulating VLDL and chylomicron particles [39, 40].
The primary components of OM3FA prescription formu-
lations, EPA and DHA, have both been shown to reduce
TG. However, they are known to have differing effects on
LDL-C and HDL-C [41–43]. In a meta-analysis comparing
the effects of DHA and EPA, in direct comparison studies,
DHA was associated with a greater reduction in TG and a
greater increase in LDL-C than EPA. DHA also raised
HDL-C compared with placebo, whereas EPA did not [42].
Further research is needed to elucidate the mechanisms
and significance of these differences [41–43].
OM3CAs have also been shown to reduce levels of
apolipoprotein CIII (ApoCIII) [44]. ApoCIII is thought to
contribute to the progression of atherosclerosis and CVD
via a number of mechanisms, including the activation
and enhancement of pro-inflammatory pathways [45]. It
also inhibits the receptor-mediated uptake of TRL and
their remnants, slowing their clearance rate, and pro-
motes the formation of small dense LDL particles from
VLDL [44, 45]. Additionally, ApoCIII is a key contributor
to hypertriglyceridemia, primarily due to its inhibitory
actions on LPL. LPL hydrolyzes plasma TRL, producing
free fatty acids, chylomicron remnants and intermediate-
density lipoproteins (IDL). Some IDL particles can also
undergo further LPL-mediated hydrolysis to produce
LDL [28]. It has been hypothesized that the differing
effects of DHA and EPA on the lipid profile may be due
to their differentiating effects on ApoCIII synthesis. DHA
is thought to reduce ApoCIII synthesis by regulating a
number of hepatic transcription factors, such as hepatic
nuclear factor-4-alpha and forkhead box-O transcription
factor O1. Therefore, DHA enhances the hydrolysis of
VLDL, resulting in greater conversion to LDL, and the
formation of larger, more buoyant LDL particles [43].
However, these effects are uncertain and warrant add-
itional investigation.
In addition to their TG-lowering effects, OM3FA are
thought to act on additional cardiometabolic risk factors,
and have been shown to significantly decrease a number
of inflammatory markers associated with atherosclerosis
and CVD. Clinical studies have demonstrated that
OM3CA and IPE decrease levels of lipoprotein-associated
phospholipase A2 (Lp-PLA2) versus placebo, and IPE has
been shown to decrease high-sensitivity C-reactive protein
[21, 23, 46]. Pre-clinical and clinical studies have also
found that EPA and DHA exhibit antiarrhythmic and
antioxidant effects [47, 48], improve endothelial function
[49, 50], and promote a less atherogenic lipoprotein
subfraction profile when administered in addition to statin
therapy [51]. They have also been shown to decrease
platelet activity biomarkers in comparison with placebo,
regardless of concomitant aspirin and statin therapy use,
and it is believed that they decrease platelet aggregation
[52]. However, DHA is thought to display more potent
anti-aggregatory effects than EPA [49, 50, 53]. In addition,
DHA has been shown to lower blood pressure and heart
rate [54–56], and seems to have a protective effect on
cognitive decline [57]. Other studies have shown an in-
verse association between carotid intima-media thickness
and OM3FA use, suggesting that OM3FA may protect
against carotid atherosclerosis [58], with data indicating a
decrease in plaque inflammation and an increase in plaque
stability [59]. Despite these proposed cardioprotective
mechanisms, to date, the effects of OM3FA-mediated TG
lowering on cardiovascular outcomes and the incidence of
pancreatitis have not yet been determined in large-scale
clinical trials [14, 16, 17, 60].
Although the majority of research on the therapeutic
potential of OM3FAs has focused on EPA and DHA,
emerging research has also begun to elucidate the mech-
anisms of DPA. DPA levels are independently associated
with a decreased risk of myocardial infarction and cor-
onary heart disease [61, 62], and low levels of DPA have
also been shown to be associated with lipid-rich plaques
and peripheral arterial disease [63, 64]. Studies have
demonstrated that EPA, DHA, and DPA dose-dependently
inhibit platelet aggregation. However, DPA was shown to
be a more potent platelet inhibitor than EPA and DHA
[65]. Like DHA and EPA, DPA has also been shown to
reduce the expression of inflammatory genes [66].
As the TG-lowering mechanism of action of long-chain
OM3FAs differs from that of other lipid-lowering drugs,
such as statins, they can potentially provide complemen-
tary benefits on the lipid profile when administered in
combination [35]. This is corroborated by the fact that the
level of TG lowering achieved with OM3FAs provides
incremental reductions in TG levels when added to statin
therapy [20, 22, 24, 67].
Bioavailability
Absorption of DHA and EPA has been shown to vary
between formulations. OM3CA have a 4-fold greater
bioavailability (area under the plasma concentration-time
curve from zero to the last measurable concentration
[AUC(0-t)]) for both EPA and DHA during low fat-
consumption periods, compared with that of OM3FA ethyl
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esters [68]. The absorption of OM3FA ethyl esters (OM3EE
and IPE) requires hydrolysis with pancreatic lipase [69, 70],
and as pancreatic lipase levels are dependent on the quan-
tity and the type of lipids ingested, the absorption of
OM3FA ethyl esters is thought to be highly dependent on
meal fat content [71, 72]. In contrast, OM3FAs in the free
fatty acid form, found in OM3CA, are not dependent on
pancreatic lipase hydrolysis. Therefore, the bioavailability of
EPA and DHA from this formulation is less dependent on
meal fat content than OM3FA ethyl esters [68]. In one
study (n = 54), under low-fat conditions, 59 % of subjects
dosed with OM3CA maintained an AUC(0-t) for EPA and
DHA of ≥50 % of the respective AUC(0-t) observed in high-
fat conditions, compared with only 6 % of subjects dosed
with OM3EE. This may confer a potential therapeutic
advantage, as current guidelines recommend that patients
with severe hypertriglyceridemia follow a very-low-fat diet
[5, 28]. This increased bioavailability, particularly during
low fat consumption, may also allow greater flexibility with
regard to dosing schedule. OM3CA have been approved to
effectively lower TG levels at doses of 2 g/day or 4 g/day, in
a once-daily dosing regimen without regard to meals [22].
Efficacy of omega-3 fatty acid formulations
The effects of the three OM3FA prescription formulations
on lipid parameters in patients with severe hypertrigly-
ceridemia are summarized in Table 2. These data are
reported in the US prescribing information for OM3EE
(Lovaza) [14], IPE (Vascepa) [16], and OM3CA (Epanova)
[17], which each summarize the results from the respec-
tive pivotal, randomized, double-blind, placebo-controlled
trials conducted in patients with baseline TG levels of
500–2000 mg/dL [18, 19, 21, 23]. It is important to note
that the type of placebo used differs among these clinical
trials, and each placebo has differing effects on TG. The
olive oil comparator used in the OM3CA trial substantially
decreased TG levels, whereas the corn oil and mineral oil
used in the OM3EE and IPE trials increased TG levels. In
patients with TG levels > 500 mg/dL, the TG reductions
observed with all prescription formulations, at doses of
4 g/day, were statistically significant compared with pla-
cebo, thus allowing the US FDA to approve these formula-
tions for adults with severe hypertriglyceridemia. As might
be expected, higher OM3FA doses and higher baseline TG
levels are associated with greater percentage TG reduc-
tions [73] (Fig. 2). Reductions in VLDL-C levels versus
placebo were also shown to be statistically significant.
It should be noted that there appears to be a tendency
for DHA-containing formulations (OM3CA and OM3EE)
to increase LDL-C versus baseline. However, importantly,
this is not associated with an accompanying increase in
non-HDL-C or ApoB, and as mentioned earlier, non-
HDL-C levels are thought to provide a better indication of
CVD risk than LDL-C levels. This is particularly the case
for patients with hypertriglyceridemia, who often have low
levels of LDL-C [5, 34]. Additionally, unlike IPE, DHA-
containing formulations increase HDL-C levels. However,
the clinical relevance of increasing HDL-C using any
pharmacologic agent remains unclear.
Similar effects on lipid parameters are observed in
statin-treated patients with high TG levels (≥ 200 mg/dL
and < 500 mg/dL) (Table 3) [20, 22, 24]. All prescription
formulations of OM3FAs at a dose of 4 g/day were shown
to significantly reduce TG, VLDL-C, non-HDL-C, and
ApoB levels in this patient population. However, in con-
trast to patients with severe hypertriglyceridemia (TG
≥ 500 mg/dL), no increase in LDL-C was observed with
any of the formulations. This is likely due to the fact that
these patients had lower baseline TG levels and were also
receiving statin therapy. The levels of TG reduction
observed with varying doses of the three OM3FA formula-
tions in patients with severe hypertriglyceridemia and high
levels of TG are shown in Fig. 2a and b.
To date, the effect of any of the prescription OM3FA
formulations on pancreatitis has not been determined.
Furthermore, no large-scale, randomized clinical trials
have provided clear evidence for the association between
TG lowering and CVD risk reduction [14, 16, 17, 60].
Two large-scale, multinational cardiovascular outcomes
studies (the Reduction of Cardiovascular Events with EPA
– Intervention Trial [REDUCE-IT; NCT01492361] [74]
and STatin Residual risk reduction with EpaNova in hiGh
cardiovascular risk paTients with Hypertriglyceridemia
[STRENGTH; NCT02104817] [75]) are currently under
way to address this question. These trials aim to evaluate
the reduction in residual risk of statin-treated patients
with high TGs treated with OM3FA. The trials will exa-
mine the safety and efficacy of prescription strength long-
chain OM3FAs in combination with statin therapy in
high-risk patients with hypertriglyceridemia, defined as
TG up to 500 mg/dL.
Omega-3 fatty acids in pediatric populations
The process of atherosclerosis can begin in early child-
hood, particularly in the presence of known cardiovas-
cular risk factors, such as obesity, hypertension, and
diabetes mellitus [76]. Studies have shown that omega-3
fatty acid supplementation can have beneficial effects on
preclinical atherosclerosis markers in children with
cardiovascular risk factors, including the prevention of
carotid artery intima-media thickness and increased
artery flow-mediated vasodilation [50, 77]. In addition,
dietary omega-3 fatty acid supplementation in infancy
has been associated with lower blood pressure in later
childhood [78, 79]. Therefore, it has been suggested that
dietary supplementation of omega-3 fatty acids in chil-
dren may improve future cardiovascular outcomes [80].
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Safety
Prescription formulations of OM3FAs are generally well
tolerated, with frequencies of treatment discontinuation
similar between the OM3FA groups and placebo groups
[81]. The most common adverse events associated with
OM3FAs are gastrointestinal in nature (including eructa-
tion, nausea, diarrhea, and other mild gastrointestinal
disturbances), and have been shown to occur in up to
Table 2 Change in lipid parameters observed with omega-3 carboxylic acids, omega-3 ethyl esters, and icosapent ethyl in patients
with severe hypertriglyceridemia (triglyceride level ≥ 500 mg/dL)
OM3CA (Epanova) [17] OM3EE (Lovaza) [14] IPE (Vascepa) [16]















Median BL, mg/dL 682 717 655 788 816 703 680
Median percentage
change from BL, %
−10 −25 −31 7 −45 10 −27
Difference‡ – −16** −21*** – −52 – −33***
Non-HDL-C
Median BL, mg/dL 215 205 225 292 271 229 225
Median percentage
change from BL, %
−1 −8 −8 −4 −14 8 −8
Difference‡ – −7* −10** – −10 – −18
HDL-C
Median BL, mg/dL 29 27 29 24 22 27 27
Median percentage
change form BL, %
2 7 5 0 9 0 −4
Difference‡ – 5† 4† – 9 – −4
Total cholesterol
Median BL, mg/dL 246 241 254 314 296 256 254
Median percentage
change from BL, %
0 −6 −6 −2 −10 8 −7
Difference‡ – −6 −9 – −8 – −16
VLDL-C
Median BL, mg/dL 125 123 126 175 175 124 123
Median percentage
change from BL, %
−11 −25 −35 −1 −42 14 −20
Difference‡ – −14 −21 – −41 – −29*
LDL-C
Median BL, mg/dL 78 77 90 108 89 86 91
Median percentage
change from BL, %
10 21 26 −5 45 −3 −5
Difference‡ – 13 15 – 49 – −2
ApoB
Median BL, mg/dL 110 114 118 ND ND 118 121
Median percentage
change from BL, %
2 6 6 ND ND 4 −4
Difference‡ – 3 2 – ND – −9*
P-values from Wilcoxon rank sum test: *P < 0.05; **P < 0.01; ***P < 0.001; †not significant. Testing for statistical significance was performed for OM3CA
(TG, non-HDL-C and HDL-C) and IPE (TG, VLDL-C, and ApoB) only. No statistical analysis was presented for OM3EE
‡Difference for OM3CA and IPE =median of [omega-3 fatty acid formulation % change – placebo % change]
(Hodges-Lehmann Estimate); Difference for OM3EE = OM3EE median % change – placebo median % change
The median placebo-corrected % change in lipid parameters reported for Omtryg, the generic form of Lovaza, are as follows: TG = −12 %,
non-HDL-C = −9 %, HDL-C = 4 %, TC = −7 %, VLDL-C = −29 %, and LDL-C = 25 % [15]
ApoB apolipoprotein B, BL baseline, HDL-C high-density lipoprotein cholesterol, IPE icosapent ethyl, LDL-C low-density lipoprotein cholesterol,
ND not described, OM3CA omega-3 carboxylic acids, OM3EE omega-3 ethyl esters, TG triglyceride, VLDL-C very-low-density lipoprotein cholesterol
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27 % of patients at doses of 4 g/day [18, 21, 23]. The most
common adverse events reported in the US prescribing
information for each formulation are summarized in
Table 4. Studies have shown that OM3FAs do not affect
liver function [18], and do not have any known clinically
significant drug–drug interactions with other commonly
used lipid-modifying drugs, such as statins [82–84]. In
contrast to a number of other TG-lowering drugs, studies
have also shown that adverse events detected in patients
receiving combination therapy with OM3FA ethyl esters
and statins were similar to those detected in patients
receiving statin monotherapy [20, 85, 86]. This is parti-
cularly advantageous when statin users with a history of
common adverse events (e.g. myalgia, elevated hepatic
transaminases) require combination therapy with a TG-
lowering drug. Additionally, although OM3FAs have been
shown to have the potential for antithrombotic effects,
they have been shown not to increase clinical bleeding,
even in patients receiving warfarin or antiplatelet drugs,
including aspirin [87–90].
Fig. 2 TG reduction observed with varying doses of omega-3 carboxylic acids, omega-3 ethyl esters, and icosapent ethyl in (a) patients with severe
hypertriglyceridemia (TG ≥ 500 mg/dL) [14, 16, 17] and (b) statin-treated patients with high baseline TG levels (TG level ≥ 200 mg/dL and < 500 mg/dL)
[20, 21, 24] Data not available for OM3EE at 2 g/day. OM3CA = Percentage change from baseline expressed as least-squares geometric mean; OM3EE =
percentage change from baseline expressed as geometric mean; IPE = percentage change from baseline expressed as median. †Placebo used = olive oil;
‡Placebo used = vegetable oil; §Placebo used =mineral oil; ǁPlacebo used = corn oil; ¶Placebo not specified. IPE icosapent ethyl, OM3CA omega-3
carboxylic acids, OM3EE omega-3 ethyl esters, TG triglyceride
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Table 3 Change in lipid parameters observed with omega-3 carboxylic acids, omega-3 ethyl esters, and icosapent ethyl in statin-treated patients with high triglyceride levels
(triglyceride level ≥ 200 mg/dL and < 500 mg/dL)
OM3CA (Epanova) [22] OM3EE (Lovaza) [20] IPE (Vascepa) [24]
Parameter Statin† + olive oil
(n = 215)
Statin† + OM3CA
2 g/day (n = 215)
Statin† + OM3CA
4 g/day (n = 215)
Simvastatin
40 mg + vegetable
oil (n = 132)
Simvastatin
40 mg + OM3EE










BL, mg/dL 280 284 287 286.7 282.0 259.0 254 264.8
% change −5.9 −14.6*** −20.6*** −3.5 −28.2*** 5.9 −5.6** −17.5***
Non-HDL-C
BL, mg/dL 135 140 139 141.3 135.8 128 128 128
% change −0.9 −3.9* −6.9*** −1.5 −7.9*** 9.8 2.4 −5.0***
HDL-C
BL, mg/dL 38.8 38.7 38.8 44.7 47.3 39.0 38.0 37.0
% change 2.2 2.6 3.3 −1.1 4.1*** 4.8 0.0 −1.0**
Total cholesterol
BL, mg/dL 174 179 178 186.0 183.1 168.0 169 167
% change 0.5 −1.7* −3.8*** −1.5 −4.7** 9.1 2.1 −3.2***
VLDL-C
BL, mg/dL 45.7 46.9 47.2 53.2 52.1 42.0 43.0 44.0
% change −5.9 −14.3** −21.5*** −4.8 −23.8*** 15.0 1.6 −12.1***
LDL-C
BL, mg/dL 91.7 92.3 93.6 92.3 89.2 84.0 82.0 82.0
% change 1.1 4.6* 1.3 −1.9 3.4 8.8 2.4 1.5**
ApoB
BL, mg/dL 93.8 94.5 95.9 86.8 85.0 91.0 91.0 93.0
% change 0.3 0.7 −2.1* −1.2 −3.8* 7.1 1.6 −2.2***
For IPE, data are presented as median; for OM3CA, data are presented as least-squares mean; for OM3EE, data are presented as geometric mean. P-values versus placebo: *P < 0.05; **P < 0.01; ***P < 0.001. †Statins
included lovastatin 20–40 mg, pravastatin 10–80 mg, fluvastatin 20–80 mg, simvastatin 10–40 mg, atorvastatin 10–40 mg, and rosuvastatin 10–40 mg, alone or in combination with ezetimibe; ‡Statins included
simvastatin, atorvastatin, and rosuvastatin, alone or in combination with ezetimibe. §Placebo not specified
ApoB apolipoprotein B, BL baseline, HDL-C high-density lipoprotein cholesterol, IPE icosapent ethyl, LDL-C low-density lipoprotein cholesterol, OM3CA omega-3 carboxylic acids, OM3EE omega-3 ethyl esters,















It is not known whether patients with allergies to fish
and/or shellfish are at an increased risk of allergic reaction
to OM3FAs, and so these formulations should be used
with caution in patients with known hypersensitivity to
fish and/or shellfish [14, 16, 17].
Dietary-supplement omega-3 fatty acids
Dietary-supplement OM3FAs are also widely utilized and
are among the most popular dietary supplements world-
wide [91]. However, dietary supplements are not subject
to rigorous regulations required for prescription drugs.
Consequently, the EPA and DHA content of dietary
supplements may be inconsistent [25–27]. Due to an early
evaluation study, practitioners typically view supplemental
OM3FAs as adequate and reliable [92]. However, a more
recent analysis of individual fish oil supplements found
that they contain an inadequate dose of EPA and DHA.
On average, they contained only 68 % of the claimed EPA
and DHA content. The same analysis also found that the
majority of supplements exceeded recommended levels of
oxidation markers [26]. As the OM3FAs undergo oxida-
tion, the concentration of EPA and DHA decreases,
suggesting reduced efficacy. One study demonstrated that
a median intake of 11 dietary fish oil supplement servings/
day was required to achieve an FDA-approved dose of
3.4 g/day of OM3FAs [27, 93]. This study also found that
dietary-supplement OM3FAs contain other fats and
cholesterol, and that the fat and cholesterol content varies
widely among products [27]. In addition, as the EPA and
DHA content of dietary supplements varies among
products, this may cause confusion for patients and
practitioners. This is likely to result in inaccurate dosing
that may potentially be inadequate to effectively lower TG
in patients with hypertriglyceridemia.
Dietary omega-3 fatty acid intake has also been shown to
play a role in cardiovascular risk reduction, with modest
fish consumption (1–2 servings per week, particularly
species high in EPA and DHA) associated with reduced risk
of coronary death and total mortality [94]. Consequently,
the AHA recommends including at least two servings of
fish (preferably oily fish) per week [95]. In addition, it
has been suggested that omega-3-enriched supplements
(nutraceuticals) and functional foods (e.g. EPA- and
DHA-enriched food products) may offer the possibility of
increased EPA and DHA consumption [96, 97]. However,
the benefits of nutraceutical products remain unclear, and
robust clinical trials are required to establish their exact
role in cardiovascular risk reduction [97].
Conclusion
In severe hypertriglyceridemia (TG ≥ 500 mg/dL), guide-
lines advocate the immediate use of a TG-lowering drug
to reduce the risk of pancreatitis. In patients with high
TG levels (≥ 200 to < 500 mg/dL), some guidelines also
recommend the use of TG-lowering drugs if elevated
TG or non-HDL-C levels persist despite lifestyle inter-
vention and statin therapy. Available TG-lowering drugs
include fibrates, niacin, and OM3FAs. Unlike fibrates
and niacin, OM3FAs do not have any known, clinically sig-
nificant drug-drug interactions with other lipid-modifying
therapies (such as statins) and do not affect liver function.
In addition, as their mechanisms of action differ from
those of other lipid-lowering drugs, they can potentially
provide complementary benefits when administered as a
combination therapy with statins.
All formulations have been shown to significantly
reduce TG levels, and despite some differences in for-
mulation, they appear to have similar efficacy. However,
OM3FAs have been shown to differ in their effects on
individual lipid parameters, their bioavailability, and the
impact of fat content of meals on absorption. Although
dietary supplements are available and widely utilized,
Table 4 Summary of adverse events observed with omega-3 carboxylic acids [17], omega-3 ethyl esters [14], and icosapent ethyl
[16] in pooled placebo-controlled trials conducted in patients with hypertriglyceridemia, based on prescribing information for
each formulation
Adverse event, % OM3CA OM3EE IPE
Adverse events occurring at an incidence ≥ 3 % Adverse events occurring
at an incidence ≥ 3 %
Adverse events occurring













IPE (n = 622)
Diarrhea 2 7 15 – – – –
Nausea 1 4 6 – – – –
Abdominal pain or discomfort 2 3 5 – – – –
Eructation < 1 3 3 1 4 – –
Dyspepsia – – – 2 3 – –
Taste perversion – – – < 1 4 – –
Arthralgia – – – – – 1 2
IPE icosapent ethyl, OM3CA omega-3 carboxylic acids, OM3EE omega-3 ethyl esters
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they are not subject to the rigorous regulations required
for prescription drugs, and therefore, their EPA and
DHA content may be inconsistent and often may not
meet label claims. All three prescription formulations of
OM3FAs currently approved for use in the US appear to
be generally well tolerated and effective in reducing TG
levels in patients with hypertriglyceridemia.
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